Genetic Testing Misses Flaws in Mutated Genes, Study Finds
Posted on: Tuesday, 21 March 2006, 21:00 CST
MILWAUKEE _ Genetic testing of women at high risk for breast cancer misses about 12 percent of flaws in two commonly mutated genes, a new study shows.
However, experts caution that testing has never been perfect and hope the findings spark development of tests with more sensitivity.
"We know abnormalities exist, we know that there are tests that can pick them up ... we need a better way of getting this knowledge from the bench to the bedside," said Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, which was not involved in the study.
About 5 percent to 10 percent of breast cancers are caused by inherited mutations in a single gene. Women with mutations in BRCA1 or BRCA2 have about an 80 percent chance of getting breast cancer in their lifetimes.
The study, which is published Wednesday in the Journal of the American Medical Association, analyzed genetic material from 300 women with at least four cases of female breast cancer, ovarian cancer and/or male breast cancer in their family. All of the women tested negative for mutations in their BRCA genes.
Using a highly specific technique known as MLPA, the researchers found that the genes of 52 women were mutated, including 35 who had changes on their BRCA gene.
"The clinical dilemma is what to offer to women with a high probability of carrying a mutation in BRCA1 or BRCA2 but with negative commercial test results," write the authors, a team of international researchers. "Technically, the answer is at hand. The mutations identified in our study that were missed by commercial testing are detectable using other approaches that are currently available."
However, the MLPA test is not clinically available in the United States.
"I suspect that there will be a significant interest in getting better tests into the mainstream," Lichtenfeld said.
Traditionally, genetic testing has proved most reliable for Jewish women of Eastern European heritage. And the best candidate for a test is a family member who already has cancer. That way clinicians are more likely to pinpoint any mutations in a culprit gene.
The decision on how to best treat women with strong family histories, but negative genetic tests for mutations has always been difficult. Typically patients are offered several options, including careful monitoring, a preventive mastectomy to remove a healthy breast, or medication such as tamoxifen, which blocks the effects of estrogen, a hormone that can fuel rapid cell growth and certain cancers.
Studies have found that prophylactic mastectomy reduces the risk of cancer, though studies involving tamoxifen for prevention are less clear.
"Even though the breast cancer is not genetic, they clearly are at risk," said Julia White, an associate professor of radiation oncology at the Medical College of Wisconsin who practices at Froedtert Memorial Lutheran Hospital.
"We all would like to have blood tests before recommending treatment, but this study tells us that there will always be genetic mutations that we don't know about," said White, who wasn't involved in the study.
Amy Stettner, a clinical genetic counselor at the University of Wisconsin Medical School in Madison, said negative test results in the face of a strong family history has always been "frustrating."
"You scratch your head and wonder, `did I test the wrong person in the family,' `does this person have breast cancer?'" she said. "Usually we're sort of left with a negative result and not knowing where to go from there."
___
(c) 2006, Milwaukee Journal Sentinel.
Visit JSOnline, the Journal Sentinel's World Wide Web site, at http://www.jsonline.com/
Distributed by Knight Ridder/Tribune Information Services.
For information on republishing this content, contact us at (800) 661-2511 (U.S.), (213) 237-4914 (worldwide), fax (213) 237-6515, or e-mail reprints@krtinfo.com.
Source: The Milwaukee Journal Sentinel
Related Articles
- Genetic Study Shows History of Latin America
- Response Genetics Study to Focus on Developing Diagnostic Test Kits for Pancreatic Cancer
- St. Louis Cancer & Breast Institute Physician Says Hormone Replacement Therapy Does Indeed Create Breast Cancer Risk
- Cancer Society's Next President Sees Medicine in Family Terms
- Breast Cancer Accounts for Almost a Third of Cancers in Women
- Preemptive surgery helps some cancer-prone women
- S.D. Firm Says Study Found Its Flu Test Highly Accurate
- Weight Linked to Breast Cancer in Women With Gene Mutation
- Matritech Announces More Than 600,000 NMP22(R) BladderChek(R) Tests Sold for Testing of Bladder Cancer
- Asian Scientists to Launch Genetic Study
User Comments (0)

RSS Feeds